AlloVir

About:

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.

Website: https://www.allovir.com

Top Investors: Fidelity, Invus, Samsara BioCapital, Gilead Sciences, ElevateBio

Description:

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials.

Total Funding Amount:

$361M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Houston, Texas, United States

Founded Date:

2013-01-01

Contact Email:

info(AT)viracyte.com

Founders:

Ann Leen, John Wilson

Number of Employees:

101-250

Last Funding Date:

2023-06-21

IPO Status:

Public

© 2025 bioDAO.ai